Gregory S. Moss
Keine laufenden Positionen mehr
Karriereverlauf von Gregory S. Moss
Ehemalige bekannte Positionen von Gregory S. Moss
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KADMON HOLDINGS, INC. | Compliance Officer | 30.08.2019 | 01.06.2022 |
General Counsel | 30.08.2019 | 01.06.2022 | |
Corporate Officer/Principal | 01.01.2015 | 30.08.2019 | |
Unternehmenssekretär | 30.08.2019 | 01.06.2022 | |
MEIRAGTX HOLDINGS PLC | Direktor/Vorstandsmitglied | 01.05.2018 | 19.06.2019 |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Compliance Officer | 01.04.2015 | 01.12.2016 |
General Counsel | 01.04.2015 | 01.12.2016 |
Ausbildung von Gregory S. Moss
Macquarie University | Graduate Degree |
Statistik
International
Cayman Islands | 2 |
Vereinigte Staaten | 2 |
Vereinigtes Königreich | 2 |
Operativ
Compliance Officer | 2 |
General Counsel | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MEIRAGTX HOLDINGS PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Gregory S. Moss
- Erfahrung